Fervent Pharmaceuticals yakazivisa nhasi kuti yatanga ongororo yayo yekiriniki kuti iongorore kushanda kwechigadzirwa chayo chekurapa kwezviratidzo zvepakati kusvika kune zvakanyanya kupisa kupisa, kudikitira husiku uye kumuka kwehusiku nekuda kwekupenya kwekupisa. Ichi chigadzirwa chakagadzirirwa kuwanikwa, kana chakabvumidzwa neFDA, kune varwere vasina kudiwa kwetsamba. Iyi mhando yekudzidza kure ndeimwe yekutanga yerudzi rwayo yakatenderwa neFDA. Varwere vari muchidzidzo ichi vachatora chikamu vari kure kubva kunyaradzo yedzimba dzavo, uko zvinhu zvese zvekuongorora zvichaunzwa, uye kubva kupi kuunganidzwa kwe data.
The M2S Hot Flash Study yakagadzirirwa kusanganisa vakadzi veperi-menopausal uye post-menopausal vanopfuura makore makumi mana nemashanu vanosangana ne45 kusvika 7 zviri pakati nepakati kusvika zvakanyanya kupisa kupenya pazuva. Vakadzi vanozadzisa maitiro aya vanogona kunyorera pa www.m8shotflashstudy.com kuti vatariswe kuti vatore chikamu muchidzidzo cheongororo iyi.
“Ndiri kufara nechigadzirwa chatiri kuferefeta pamwe nemikana yachingave nacho mukusimudzira hupenyu hwevarwere ava. Kupfuurirazve, kuve nedhizaini yekudzidza inounza kurerukirwa kwekutora chikamu zvakananga mudzimba dzevarwere kunobvumira varwere vazhinji kuti vatore chikamu, uye vanozviita pamarongwa avo," George Royster, Muvambi / CEO weFervent Pharmaceuticals, akadaro. “Tinofara zvikuru kuti chidzidzo ichi chiitwe nekuvandudza hupenyu hwemadzimai kuburikidza nemishonga mitsva yezviratidzo zvekusiya kumwedzi.”
Kuedzwa kwemavhiki matatu kuri kuitwa kuti kuwanikwe kune vanokodzera kutora chikamu munyika yose. Vatori vechikamu vachakumbirwa kuti vatarise zviratidzo zvavo zvevasomotor online panguva yekuedzwa uye kupedzisa ongororo pakupera kwechidzidzo. Zvigadzirwa zvekuferefeta zvichapihwa zvinosanganisira mumuromo, isiri-hormonal, isiri-herbal, isiri-antidepressant kuumbwa kwekomboni inoziva nzira dzekuita, yakatoshandiswa zvakanyanya kune imwe chiratidzo, uye ine nhoroondo refu yekushandiswa kwakachengeteka. . Zvishandiso zvekuyedza zvichasanganisira zvekudzidzisa kudzidzisa vatori vechikamu mashandisirwo esoftware yemurwere wetsvakurudzo.
Fervent Pharmaceuticals ikambani inogadzira zvinodhaka padanho rekiriniki yakavambwa kuNorth Carolina muna 2011. Yakanangana nekusimudzira hupenyu hwevakadzi nekugadzira mishonga inonangana nezvido zvisina kuzadziswa muutano hwevakadzi.
ZVOKUBVA MUNYAYA INO:
- The investigational products to be provided include an orally dosed, non-hormonal, non-herbal, non-antidepressant formulation of a compound that has known mechanisms of action, is already widely used for a different indication, and has a long history of safe use.
- The M2S Hot Flash Study is designed to include peri-menopausal and post-menopausal women over the age of 45 who experience at least 7 to 8 moderate to severe hot flashes per day.
- Fervent Pharmaceuticals announced today that it has commenced its virtual clinical study to evaluate the effectiveness of its novel product for the treatment of the symptoms of moderate to severe hot flashes, night sweats and nighttime awakenings due to hot flashes.
